Arvind Lal
Arvind Lal is an Indian physician and businessman who built Dr Lal PathLabs into one of the largest diagnostic testing chains in India. He has served as chairman of the company and previously as its managing director, and was awarded the Padma Shri, one of India's higher civilian honours, in 2009 for services to medicine.
The company originated as a single pathology laboratory opened in Delhi in 1949 by his father, Dr S. K. Lal. Under Arvind Lal it grew into a national network of laboratories and collection centres, listed on the Indian stock exchanges in December 2015, and became the standard example of how a fragmented professional service can be organised into a branded national business.
Early life and education
Lal was born in 1949, the year his father established the laboratory that became the family business. He qualified in medicine and trained in pathology, and served in the Indian Army Medical Corps, reaching the rank of captain before leaving to take over the family practice.
The medical qualification matters to how the business developed. Lal has consistently presented the company as a medical organisation that happens to be commercial rather than the reverse, and the distinction bears on the principal criticism of the sector, which concerns the incentives created when testing is sold rather than prescribed.
Career
Building the network
Lal joined the family laboratory in the late 1970s. At that point it was a single establishment of the kind found in every Indian city: a pathologist, a small laboratory and a local reputation.
The transformation rested on two ideas.
The first was the hub and spoke model. Rather than replicating a full laboratory in every location, which is expensive because the equipment is costly and requires volume to be justified, the company built a small number of large reference laboratories capable of performing the full range of tests, a larger number of regional laboratories performing common tests, and a very large number of collection centres, which are small premises where a sample is taken and then transported to a laboratory. The model allows the expensive capacity to be used intensively while the customer-facing points can be opened cheaply and in large numbers.
The second was branding a commodity. A blood test is, in principle, the same wherever it is performed, and Indian patients had historically had no way to judge the reliability of a local laboratory. By building a national brand associated with accreditation, standardised procedure and consistent reporting, the company gave patients and referring physicians a reason to choose it over a cheaper local alternative, and gave itself pricing power in a market that would otherwise have competed only on cost.
Accreditation was central to this. The company pursued certification from the National Accreditation Board for Testing and Calibration Laboratories and from the College of American Pathologists, and used it as a marketing proposition as much as a quality assurance measure.
Expansion and listing
Growth accelerated after private equity investment from WestBridge Capital and later from TA Associates during the 2000s, which funded the expansion of the network beyond northern India.
Dr Lal PathLabs listed on the National Stock Exchange and the Bombay Stock Exchange in December 2015. The offering was substantially oversubscribed and the shares rose sharply on debut, reflecting investor appetite for a branded consumer healthcare business in a market where most healthcare provision remained fragmented and informal.
The company subsequently expanded through acquisition, most significantly of the Suburban Diagnostics business in western India in 2021, and through further extension of its collection network, reaching thousands of centres nationally.
The pandemic
The coronavirus pandemic was, commercially, transformative and then destabilising. Demand for testing rose enormously during 2020 and 2021, and diagnostic chains including Dr Lal PathLabs reported revenue and profit far above any previous level. The subsequent normalisation was abrupt, and the sector's share prices fell considerably as it became clear that the elevated volumes would not persist.
The pandemic also changed the competitive landscape permanently. It accustomed a very large number of Indian consumers to booking a test directly, without a physician's referral, and to having a sample collected at home, which opened the market to online health platforms and to well-funded new entrants competing aggressively on price. The established chains, which had built their positions on physician relationships and on brand, faced competition of a kind they had not previously encountered.
Governance and succession
Lal has moved from executive leadership towards the chairmanship, with professional management appointed to run the company's operations and members of the family retaining board involvement, a transition of a kind that Indian promoter-founded companies have often found difficult and that the company has executed comparatively smoothly.
The Indian diagnostics sector
Dr Lal PathLabs is best understood against the structure of Indian healthcare.
The great majority of Indian healthcare spending is private and paid directly by patients, since insurance coverage, though growing, remains limited. Diagnostic testing is a large component of that spending and is highly fragmented: the sector comprises tens of thousands of standalone laboratories, most of them small, alongside hospital laboratories and a small number of national chains, of which Dr Lal PathLabs, Metropolis Healthcare and SRL Diagnostics are the largest.
The organised chains hold a modest share of the total market, which is the basis of the growth argument made for them: as incomes rise, as insurance spreads and as patients become more concerned with reliability, share should shift from unbranded local laboratories to accredited national ones. That argument has held for two decades, though more slowly than its advocates expected.
The sector's persistent criticism concerns incentives. Where a laboratory pays a commission to the physician who refers a patient, a practice long widespread in India and formally prohibited, testing is driven by the referrer's income rather than by clinical need. The larger chains have positioned themselves against the practice, partly on ethical grounds and partly because their brand strategy depends on patients choosing them directly rather than being sent. A related concern attends the marketing of preventive health packages directly to consumers, which may generate testing with no clinical indication.
Recognition
Lal received the Padma Shri in 2009. He has held positions in professional and industry bodies, including in the healthcare committees of the Confederation of Indian Industry and the Associated Chambers of Commerce and Industry of India, and has been involved in the development of accreditation and quality standards for Indian laboratories.
Assessment
Lal's achievement was to see that a fragmented professional service could be industrialised without becoming impersonal, and to execute that over four decades rather than through a rapid roll-up.
The hub and spoke structure is now standard across Indian diagnostics and in comparable markets elsewhere, and the insistence on international accreditation raised the standard expected of laboratories across the sector, including those that never joined a chain. The business he built is genuinely national in a country where very few consumer healthcare organisations are.
The challenges facing it are not of his making and are substantial. Competition from technology-funded entrants willing to sustain losses to acquire customers has compressed prices. The pandemic pulled forward a great deal of demand and habituated consumers to buying tests directly, which weakens the physician relationship on which the chains were built. And the regulatory environment for diagnostic pricing in India remains unsettled.
That a single laboratory opened in Delhi in 1949 became a listed company operating across the country is nonetheless among the clearer instances of institution-building in Indian healthcare, and it was accomplished in a sector that most investors ignored until it had already happened.